Tracer library / [177Lu]Lu-DOTA-iPD-L1

[177Lu]Lu-DOTA-iPD-L1

Also written as [Lu-177]Lu-DOTA-iPD-L1

Radionuclide: Lu-177 t½ 9584.6 min
Modality: Therapy
Production route: —
Stage: Preclinical
Syntheses indexed: 1

Breast cancer Immune cell and immunotherapy imaging Preclinical only, no clinical indication yet

What it is

Compound class: PD-L1 inhibitor cyclic peptide conjugated with DOTA chelator
Target / mechanism: Targets programmed cell death ligand-1 (PD-L1), overexpressed in certain tumors, which inhibits immune response PMID 40733128
Clinical application: PD-L1-overexpressing tumors, in combination with anti-PD-L1/PD1 immunotherapy PMID 40733128
Theranostic pair: —

Published syntheses

Module	Cassette	Purification	Yield %	RCP %	Precursor / supplier	Source
Manual synthesis	—	HPLC	—	98.9 ± 1.1%	DOTA-iPD-L1	40733128 2025 Pharmaceutics [177Lu]Lu-DOTA-iPD-L1 was also prepared for comparative imaging studies, as previously reported [12]

Need this precursor?We can point you to suppliers for [177Lu]Lu-DOTA-iPD-L1, or handle the enquiry for you.

Get in touch

Notes

Added at stage 22: promoted from 'Reported once' (single-article, no diagnostic pair at discovery) because a full-text synthesis with extracted data exists in parsed-therapy.xlsx -- PMID(s): 40733128. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Stage set/updated at stage 39 from PMID 40733128: 'Biodistribution in mice bearing 4T1 tumors was performed, and molecular imaging (Cerenkov images) of [18F]AlF-NOTA-iPD-L1 and [177Lu]Lu-DOTA-iPD-L1 in the same mouse was obtained.'.